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Abstract: In this study, we utilized an integrated bioinformatics and computational biology approach in search of new
BH3-only proteins belonging to the BCL2 family of apoptotic regulators. The BH3 (BCL2 homology 3) domain mediates
specific binding interactions among various BCL2 family members. It is composed of an amphipathic α-helical region of
approximately 13 residues that has only a few amino acids that are highly conserved across all members. Using a
generalized motif, we performed a genome-wide search for novel BH3-containing proteins in the NCBI Consensus
Coding Sequence (CCDS) database. In addition to known pro-apoptotic BH3-only proteins, 197 proteins were recovered
that satisfied the search criteria. These were categorized according to α-helical content and predictive binding to BCL-xL
(encoded by BCL2L1) and MCL-1, two representative anti-apoptotic BCL2 family members, using position-specific
scoring matrix models. Notably, the list is enriched for proteins associated with autophagy as well as a broad spectrum of
cellular stress responses such as endoplasmic reticulum stress, oxidative stress, antiviral defense, and the DNA damage
response. Several potential novel BH3-containing proteins are highlighted. In particular, the analysis strongly suggests
that the apoptosis inhibitor and DNA damage response regulator, AVEN, which was originally isolated as a BCL-xLinteracting protein, is a functional BH3-only protein representing a distinct subclass of BCL2 family members.

Keywords: Apoptosis, autophagy, DNA damage checkpoint.
INTRODUCTION
Members of the B-cell lymphoma-2 (BCL2) family of
proteins are characterized by conserved regions known as
BCL2 homology (BH) domains (designated BH1, BH2, BH3
and BH4). Multiple BH domain-containing proteins include
the anti-apoptotic proteins BCL2, BCL-xL, BCL-w, MCL-1
and A1/BFL-1 and the pro-apoptotic proteins BAX, BAK,
BCL2L14/BCL-G and BOK. By comparison, a subclass of
pro-apoptotic BCL2 family members, referred to as BH3only proteins, possess only the BH3 domain. Members of
this subclass include BAD, BBC3/PUMA, BCL2L11/BIM,
BCL2L15/BFK, BMF, BID, BIK, HRK and PMAIP1/
NOXA [1, 2]. Structural studies have shown that the BH3
domain of BH3-only proteins binds as an amphipathic αhelix in a hydrophobic groove of anti-apoptotic BCL2 family
members [3] and there is some evidence to suggest that the
affinity of a BH3 domain peptide for anti-apoptotic BCL2
proteins is influenced by the tendency of the peptide adopt
the α-helical conformation required for binding [4, 5].
Day and coworkers have described a generalized motif
composed of 13 residues that covers approximately two
heptads of the α-helix of BH3 domains, Φ1ΣXXΦ2XXΦ3Σ’
DZΦ4Γ, where Φ1-Φ4 are hydrophobic residues, Σ and Σ’ are
small residues, X is any amino acid, D is a conserved aspar*Address correspondence to this author at the Department of Anatomy and
Regenerative Biology, George Washington University, 2300 I Street NW,
Washington, DC 20037, USA; Tel: 202-994-3511; Fax: 202-994-8885;
E-mail: rghawley@gwu.edu
†

Current address: Ira A. Fulton Schools of Engineering, Arizona State
University, Tempe, AZ 85287, USA
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tic acid, Z is usually an acidic residue and Γ is a hydrophilic
residue capable of forming an intermolecular helix cap [6].
In all bona fide BH3-only proteins, the Φ2 hydrophobic
residue is a leucine (L) [7]. The conserved L and D residues
form key interactions with the cognate anti-apoptotic protein.
L is buried in the protein-protein interface and packs against
conserved residues provided by the anti-apoptotic protein,
while the solvent-exposed D forms an ionic interaction with
a conserved arginine in the BH1 domain of the anti-apoptotic
protein [8]. Other binding interactions arise from the Φ1, Φ3
and Φ4 hydrophobic residues. All anti-apoptotic proteins use
the equivalent hydrophobic groove interface to bind multiple
BH3-only proteins but they have distinct BH3 binding
profiles [9-11]. In this regard, introducing two or three mutations into the BIM BH3 sequence can generate considerable
selectivity for BCL-xL relative to MCL-1 or vice versa [12,
13]. Recently, Dutta and colleagues combinatorially mutated
all four hydrophobic residues (Φ1-Φ4), the conserved D, and
a sixth position of the BIM BH3 domain (X at position 3b
according to their numbering convention; see Fig. 1) and
used yeast surface display to identify peptides selective for
binding to BCL-xL or MCL-1 [11]. They complemented this
approach by performing binding assays with BCL-xL or
MCL-1 and peptide arrays spotted with BIM BH3 peptides
in which 10 of the 13 residues (including the 6 randomized
in the yeast surface display library) were individually
mutated. Using the combined data, they developed positionspecific scoring matrix (PSSM) models for BH3 binding
specificity for BCL-xL and MCL-1.
Our group has a long-standing interest in the molecular
mechanisms underlying growth and survival of malignant
cells [14-18]. Here we describe an approach that combines
2012 Bentham Open
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BH3 Motif

Human
Chimpanzee
Dog
Mouse
Chicken
Fruit fly

118
114
134
106
112
91

---2------3------4--abcdefgabcdefgabcdefg
WDRYQDIEKEVNNESGESQRGTDFSVLLSSAGDSFSQFRFAEEKEWDSEA
WDRYQDIEKEVNNESGESQRGTDFSVLLSSAGDSFSQFRFAEEKEWDSEA
WDRYQDIEKEVNNESGESQRGTDFSVLLSSAGDSFSQFRFVEEKEWDGEV
WDRYQDTEKEVNGESGESQRGTDFSVLLSSAGDSFSQFRFAEEKEWDGET
WNRYEDAEKEGQTECGESQRGTDFSVLLSSAGDSFSQFRFAEEKDWDTEN
VEQLGLDGAPIDENARAQLRAGDFQQLAQFPSLGGGHFTFGSEREWANVA

167
163
183
155
161
140

Region II
Fig. (1). Alignment of AVEN proteins of human (NP_065104.1), chimpanzee (XP_510277.3), dog (XP_535418.2), mouse (NP_083120.2),
chicken (NP_001005791.1) and fruit fly (NP_572817.1). Conserved BH3-like motifs in the human, chimpanzee, dog, mouse and chicken
proteins are highlighted in blue with conserved L and D residues in red. Numbering using the heptad convention of Dutta and colleagues
[11] is shown at the top. Note that the Drosophila protein has diverged considerably from the other proteins and does not contain a putative
BH3 motif, but some common residues have been retained within the boxed region (referred to as Region II by Zou and colleagues [34]).
The 25-mer AVEN and dAven peptides used in the molecular dynamics simulations of putative BH3 interactions with BCL-xL (Fig. 3) are
underlined.

genome-wide consensus BH3 motif searching, α-helical
secondary structure prediction and predictive PSSM models
of binding to BCL-xL and MCL-1 in an attempt to identify
novel BH3-containing proteins involved in cancer pathobiology and therapeutic response.

score contributions of all 10 positions predicted by the
revised PSSM model that incorporated 170 single-site mutations plus selected sequences based on combinatorial
mutations identified by yeast surface display [11].
Molecular Dynamics Simulations

MATERIALS AND METHODOLOGY
Bioinformatics
A search for new BH3-containing BCL2 family members
was conducted using the NCBI CCDS database (http://www.
ncbi.nlm.nih.gov/projects/CCDS/CcdsBrowse.cgi) for proteins containing 13-amino acid sequences that match a
consensus BH3 motif, Φ1ΣXXΦ2XXΦ3Σ’DZΦ4Γ, based on
that described by Day and colleagues [6] with the following
modifications: Φ1 represents ACGILMFPWVYET (BNIP1/
BNIP3L has E; HRK has T) [13]; Φ2 is L; Φ3 represents
ACGILMFPWVYETS (BECN1 has T; BNIP3L has S) [13];
Φ4 represents ACGILMFPWVYET [13]; Σ represents
GASCV (BOK has C; BCL2L14/BNIP3L have V); Σ’
represents GASC; X is a random amino acid; D is a
conserved aspartic acid; Z represents DEKQLSW (NOXA
has K; BCL2L14/BCL2L15/BMF have Q; BBC3/BECN1
have L; BID has S; BNIP3L has W); and Γ represents an
amino acid which is capable of forming an intermolecular
helix cap, NDSTCGHYEV [19] .
The helical content of the putative BH3 sequences was
determined from secondary structure predictions of all of the
human protein sequences in the NCBI CCDS database using
PredictProtein (www.predictprotein.org) PROFphd neural
network secondary structure prediction software [20].
PSSM models derived by Dutta and colleagues were used
to predict binding to BCL2L1/BCL-xL and MCL-1 [11]. The
PSSM models were built using peptide array data from point
mutations made in the background of a peptide derived from
the BH3 region of BCL2L11/BIM (involving 10 positions2d, 2e, 2g, 3a, 3b, 3d, 3e, 3f, 3g, 4a-mutated to any of
ADEFGHIKLNPQRSTV). The binding affinity score presented for each putative BH3 sequence is the sum of the

Molecular dynamics simulations of interactions between
putative BH3 sequences and anti-apoptotic BCL2 family
members were carried out essentially as we have described
previously [21] except that GROMACS (Groningen Machine
for Chemical Simulations) was used as the modeling
software (www.gromacs.org) [22]. The starting coordinates
for the simulations of the binding of the 25-mer AVEN and
dAven peptides to BCL-xL were based on the BAD/BCL-xL
complex (PDB code: 1G5J) [4]. The backbone conformation
for the two peptide ligands ESQRGTDFSVLLSSAGDSF
SQFRFA (AVEN) and AQLRAGDFQQLAQFPSLGGGHF
TFG (dAven) was obtained from amino acids 301-325 of
BAD with all sidechains rebuilt using the SCAP sidechain
prediction program [23]. The GROMACS96 53a6 force field
and Simple Point Charge (SPC) water model were chosen
for the simulations. Using the “Pdb2gmx” tool available in
GROMACS, hydrogen atoms present in the file were
removed and then rebuilt according to the description in the
force field. Energy minimization was performed on the
initial structure of the ligand and receptor complex to relax
possible strain after adding the force field and water model
by using steepest-descent integration. The system was
equilibrated for a period of 0.5 ns. The complex was then
placed in the center of a cubic water box and the solute
molecules were solvated with SPC water molecules using the
GROMACS utility program “Genbox”. The total number of
atoms in the two simulations varied between 26,000 and
27,000. The system was neutralized by adding Na+ or Clions to a concentration of 0.15 M NaCl using the
GROMACS utility program “Genion”. In some simulations,
excess Na+ or Cl- ions were added. This step was followed
by an energy minimization and a position relaxation simulation, each for 0.5 ns. Afterwards, the system was equilibrated
for a period of 1 ns in two stages. First, a 0.5 ns stage
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simulation was performed under the NVT ensemble (constant number of atoms, volume and temperature), relaxing the
system and coupling it to the heat bath. The second stage
consisted of a further 0.5 ns simulation without any restraints
using the NPT ensemble (constant number of atoms, pressure and temperature). Production runs constituted 20 ns of
simulations under NPT conditions. The LINCS algorithm
[24] was used to constrain all bonds involving hydrogen
atoms. Periodic boundary conditions were applied in all
three directions. The simulation temperature and pressure
were 300 K and 1 bar, respectively. Temperature was
maintained by using the Berendsen algorithm [25] with a
coupling constant of 0.1 ps during the equilibration and
production stages. For pressure coupling, the Berendsen
algorithm with a coupling constant of 1.0 ps was adopted to
maintain the boundary pressure. Non-bonded interactions
were evaluated using a spherical cutoff of 14 Å. A time step
of 0.001 ps was used for the simulations.

Hawley et al.

tional protein involved in cell death and the DNA damage
checkpoint (Supplemental Files 1 and 2).
A PSSM was used to predict binding to BCL2L1/BCLxL and MCL-1. The PSSM was derived by Dutta and colleagues from binding analyses using peptide arrays and yeast
surface display in which the effects of single-site and combinatorial point mutations were assessed in the background of
a peptide corresponding to the BH3 region of BCL2L11/
BIM [11]. A prediction could be made for 111 of the 197
candidates, and these are listed in Supplemental File 2 (pages
6-45) in the descending order of their binding affinity scores
for BCL2L1/BCL-xL. For the remaining candidates (86
genes), a prediction was not possible because at least one of
the amino acids in the motif was not contained in the PSSM
matrix (Supplemental File 2, pages 46-72). Below we
highlight several of these proteins as potential new BH3containing BCL2 family members.
Putative BH3-Containing BCL2 Family-Binding Proteins

RESULTS AND DISCUSSION
Bioinformatics Search for Novel BH3-Only Proteins
By using a relaxed consensus sequence corresponding to
BH3-containing pro-apoptotic BCL2 family members (see
Materials and Methodology), we conducted a search of the
NCBI CCDS database. A total of 279 sequences were
recovered representing 214 genes (17 known BH3-containing genes and 197 potential BH3-only protein candidates)
that satisfied the search criteria. As expected, included in this
list were all of the known pro-apoptotic BH3-only proteins
(BAD, BBC3/PUMA, BCL2L11/BIM, BCL2L15/BFK,
BMF, BID, BIK, HRK, and PMAIP1/NOXA). Also present
in the list were the multidomain pro-apoptotic proteins BAK,
BAX, BCL2L14/BCL-G and BOK. In addition, two BH3containing proteins involved in autophagy, BECN1 and
BNIP3L/NIX, were identified as were the previously recognized BH3-containing proteins HUWE1/MULE, an E3
ligase that ubiquitinates MCL-1, and RAD9A, a multifunc-

AVEN (Apoptosis, Caspase Activation Inhibitor)
AVEN (also known as PDCD12; programmed cell death
12) is a novel apoptosis inhibitor which binds to both BCLxL and the caspase regulator, apoptotic peptidase-activating
factor-1 (Apaf-1) [26]. AVEN has been proposed to inhibit
apoptosis in part by stabilizing BCL-xL [27]. Apaf-1 is a
pro-apoptotic protein that accelerates apoptosis downstream
of mitochondria by multimerizing to form the apoptosome
complex, which activates caspase proteases [28]. AVEN
interferes with the ability of Apaf-1 to self-associate, suggesting that AVEN also impairs Apaf-1-mediated activation
of caspases [26].
AVEN was identified in a yeast two-hybrid screen with
BCL-xL as bait; the gene is broadly expressed and is conserved in other mammalian species. Indirect immunofluorescence analysis indicated a diffuse nuclear staining pattern
and a reticular cytoplasmic staining pattern consistent with
intracellular membrane localization [26]. We identified a

AVEN
BIK

MQAERGARGGRGRRPGRGRPGGDRHSERPGAAAAVARGGGGGGGGDGGGRRGRGRGRGFR 60
------------------------------------------------------------

AVEN
BIK

GARGGRGGGGAPRGSRREPGGWGAGASAPVEDDSDAETYGEENDEQGNYSKRKIVSNWDR 120
-----------------------MSEVRPLSRDILMETLLYEQLLEP--PTMEVLGMTDS 35
.
*:. *
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*: :
.. :::. *

AVEN
BIK

YQDIEKEVNNESGESQRGTD-FSVLLSSAGDSFSQFRFAEEKEWDSEASCPKQNSAFYVD 179
EEDLDPMEDFDSLECMEGSDALALRLACIGDEMDVSLRAPRLAQLSEVAMHSLGLAFIYD 95
:*::
: :* *. .*:* ::: *:. **.:.
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**.: . . ** *

AVEN
BIK

SELLVRALQELPLCLRLNVAAELVQGTVPLEVPQVKPKRTDDGKGLGMQLKGPLGPGGRG 239
QTEDIR-----------DVLRSFMDGFTTLKENIMRFWRS-------------------- 124
.
:*
:* .:::* ..*:
:: *:

AVEN
BIK

PIFELKSVAAGCPVLLGKDNPSPGPSRDSQKPTSPLQSAGDHLEEELDLLLNLDAPIKEG 299
--------------------PNPGS-----------WVSCEQVLLALLLLLALLLPLLSG 153
*.**.
: :::
* *** * *: .*

AVEN
BIK

DNILPDQTSQDLKSKEDGEVVQEEEVCAKPSVTEEKNMEPEQPSTSKNVTEEELEDWLDS 359
GLHLLLK----------------------------------------------------- 160
. * :

AVEN
BIK

MIS 362
---

Fig. (2). ClustalW2 (http://www.ebi.ac.uk/Tools/msa/clustalw2/) sequence alignment of AVEN versus BIK. “*”, identical; “:”, conserved
substitutions; “.”, semi-conserved substitutions. The putative BH3-like motif in AVEN and the BIK BH3 domain are highlighted.
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putative BH3 motif in AVEN encompassing amino acids
141-153 (FSVLLSSAGDSFS; Fig. 1). Although BH3-only
proteins share homology mainly in the BH3 region [1,29], it
is noteworthy that further sequence similarity can be found
between AVEN and BIK [30] outside of the BH3 motif
(58% similarity over a 77 amino acid region encompassing
the putative BH3 motif (Fig. 2). The putative AVEN BH3
motif contains two amino acids that are associated with
BCL-xL specificity (FSVLLSSAGDSFS) according to
binding studies carried out by Dutta and colleagues [11].
According to the PSSM model, AVEN would be predicted to
bind BCL-xL with higher affinity than BCL2L14/BCLG
[31] (see Supplemental File 2).
Chau and coworkers reported that AVEN binding to
BCL-xL involved both the BH1 and BH4 domains of BCLxL [26]. The BH1 domain is part of the hydrophobic groove
that binds BH3 motifs [32], suggesting a BH3-mediated
interaction. N136 of BCL-xL forms a hydrogen bond with a
carboxylate group of the conserved D in the BH3 motif [32].
Mutation of N136 to I eliminates this and leads to loss of a
stabilizing interaction. One of the BCL-xL mutants that
Chau and colleagues used that disrupted the BCL-xL-AVEN
interaction (BCL-xL mutant 7) contained the N136I mutation (V135A/N136I/W137L). Additionally, because AVEN
bound to a deletion mutant of BCL-xL encompassing amino
acids 26-83 but not to an N-terminally truncated mutant
missing the first 61 amino acids, the N-terminal 25 amino
acids of BCL-xL were implicated in the interaction. The Nterminal 25 amino acids of BCL-xL comprise the BH4
domain, suggesting a potential interdependency of the BCLxL-AVEN interaction interfaces similar to that described
between BCL2 and BAX [33]. Consistent with the above
speculation, the putative BH3 motif is conserved in Aven
molecules across species (referred to as Region II in Fig. 1 of
Ref. [34]). The exception to this is the Drosophila ortholog
of Aven (dAven) that was recently identified by Zou and
coworkers [34]. Interestingly, the Drosophila protein does
not contain a recognizable BH3 motif: the conserved L and
D residues as well as other amino acids are not preserved
(e.g., an F at position 4a that AVEN shares with BIM and
BAD and which makes a significant hydrophobic contribution to the BH3 domain interactions of these proteins; Supplemental File 1) (Fig. 1).
Recent molecular dynamics simulations of pro-apoptotic
BH3 peptide helices in aqueous medium have suggested a
relationship between helix stability and their binding affinities to BCL-xL. Lama and Sankararamakrishnan speculated
that unlike the situation when the BH3 domains are part of a
polypeptide chain and the hydrophobic residues insert
themselves into the hydrophobic groove of an anti-apoptotic
BCL2 family member, small peptides exposed to aqueous
medium are likely to cluster among themselves to minimize
contact with water molecules [5]. Therefore, the peptide
simulations conducted represented an unfolding study and
the authors were able to correlate the helical state of the BH3
peptide at the end of the simulation with its experimental
binding affinity for BCL-xL [4,5]. The stable helical segment that was found to be common to all the BH3 peptides is
composed of a short five residue region with the conserved L
located in the center, and they speculated that the conserved
L could serve as a nucleation signal for an eventual longer
helix upon binding to BCL-xL. We carried out molecular
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dynamics simulations of BCL-xL in complex with a 25-mer
corresponding to the putative BH3 motif of AVEN and the
corresponding region of dAven (highlighted in Fig. 1) [35].
As can be seen in Fig. 3, whereas the AVEN peptide
exhibited significant internal helical stability at the end of
the simulation period (Fig. 3A), there was almost a complete
loss of helical character of the dAven peptide (Fig. 3B).
Based on Lama and Sankararamakrishnan’s work [5,35],
dAven would be predicted to have significantly reduced (if
any) binding affinity for BCL-xL. Experimental data
supports this prediction. In contrast to AVEN, no interaction
was found between dAven and Drosophila BCL2 family
members [34].

Fig. (3). Results of molecular dynamics simulation of putative
AVEN BH3 motif with BCL-xL. (A). Ribbon diagram of a peptide
encompassing the putative BH3 motif of human AVEN
(ESQRGTDFSVLLSSAGDSFSQFRFA; shown in red) complexed
with BCL-xL. (B) Ribbon diagram of the corresponding peptide
from Drosophila Aven (AQLRAGDFQQLAQFPSLGGGHFTFG;
shown in red). See Fig. (1) and text for details. Simulations (20 ns)
are based on an analogous 25-mer of the BAD BH3 motif and the
BAD/BCL-xL structure (PDB code: 1G5J).

Collectively, these enticing correlations raise the strong
possibility that the BH3 motif in AVEN is a functional BH3
domain and that AVEN is a novel BH3-only protein. In
addition to anti-apoptotic activity, AVEN also exhibits cell
cycle regulatory function. After DNA damage, AVEN
induces cell-cycle arrest via ataxia-telangiectasia-mutated
(ATM) kinase activation [36]. A working hypothesis is that
human AVEN (and most Aven orthologs) is a multifunctional protein that modulates decisions of cell-cycle arrest
and apoptosis during the DNA damage response, depending
on the extent of damage [37]. In this regard, AVEN exhibits
some striking functional similarities with RAD9A [38-40];
additional analogies can be drawn between AVEN and BID
[41,42].
GRAMD4
Proteins containing GRAM (Glucosyltransferases, Rablike GTPase activators and Myotubularins) domains are
predominately involved in membrane-associated processes
[43]. GRAMD4 was originally identified as a downstream
pro-apoptotic target of the transcription factor E2F1 (termed
Death-Inducing-Protein), which localizes to mitochondria
[44]. Upregulation of endogenous GRAMD4 by E2F1
activation or GRAMD4 overexpression demonstrated greatly
reduced cell viability in several in vitro systems accompanied by typical apoptotic features such as caspase-3
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activation and cleavage of poly(ADP-ribose)-polymerase.
Inhibition of endogenous protein function by small interfering RNA rescued p53-negative cells from E2F1-induced
apoptosis, indicating that GRAMD4 is an essential mediator
of the p53-independent E2F1 death pathway.
Recent studies by the same group have provided evidence that GRAMD4 is a p73 primary-response gene [45].
Pützer and colleagues showed that GRAMD4 is highly efficient in inducing mitochondrial outer membrane permeabilization with release of the intermembrane space proteins
cytochrome c and Smac/Diablo into the cytoplasm. Overexpression of p73α and p73β isoforms, but not p53, led to
direct GRAMD4 promoter transactivation. GRAMD4 was
found to physically interact with BCL2, promoting BAX
mitochondrial relocalization and oligomerization. In addition, GRAMD4 induced changes in BCL2 and BAX protein
levels independent of transactivation effects at the level of
the BCL2 or BAX promoters, suggesting that GRAMD4 is
functioning through indirect perhaps post translational
mechanisms, consistent with its apparent lack of a DNA
binding and transactivation domain [44].
Our analysis identified a putative BH3 motif in
GRAMD4 encompassing amino acids 218-230 (FVKNL
SALSDWYS). It is noteworthy that, with the exception of
BECN1, in all of the bona fide BH3-only genes reported to
date, the BH3 domain is a structural and functional subunit
encoded by a single short exon [29]. As shown in Table 1,
the putative BH3 motif in GRAMD4 satisfies this condition.
Although the authors did not detect a BH3 domain upon
inspection of the protein, they reported that deletion of a
region encompassing amino acids 92-176 disrupted the

interaction of GRAMD4 with endogenous and ectopically
expressed BCL2 protein. It remains to be demonstrated, but
a possibility is that the 92-176 amino acid deletion in
GRAMD4 led to a conformational change in the putative
BH3 domain disrupting the interaction with the BH1-BH3
hydrophobic groove interface of BCL2 [33,46].
HIP1R
HIP1R (Huntingtin interacting protein 1 related) is a
multi-domain protein that regulates clathrin-mediated endocytosis and actin assembly [47]. The related HIP1 protein
was identified as an interactor of huntingtin, a protein that
when mutated is involved in the genetic neurodegenerative
disorder Huntington’s disease [48,49]. The mutated
huntingtin has reduced affinity for HIP1, suggesting that the
impaired interaction could be part of the disease mechanism
[49]. HIP1R was identified on the basis of structural
homology to HIP1 [50,51]. Both proteins have an Nterminally localized ANTH (AP180 N-terminal homology)
domain, a central coiled-coil domain, and a talin-like domain
at the C-terminus. HIP1R binds inositol lipids via the ANTH
domain [52] and actin via its talin like-domain [53]. In
contrast to HIP1, HIP1R does not directly bind huntingtin
[54].
HIP1 was previously shown to have transforming function due to alterations in receptor trafficking [55]. Other
work studying ANTH domains, suggested a mechanism by
which the protein might facilitate cell survival by stabilizing
receptor tyrosine kinases by binding 3-phosphorylated
inositol lipids [56]. Hyun and coworkers provided evidence
in support of such a mechanism for both HIP1 and HIP1R
[52]. The authors speculated that HIP1 and HIP1R might

Table 1. BH3 Motifs Encoded by a Single Exon
SDALALRLACIGDEMDVSLRAPRLAQLSEVAMHS
VLGKAVHSLSRIGDELYLEPLEDG
STMGQVGRQLAIIGDDINRRYDSEFQTMLQHLQPTAENAYEYFTKIATS
ELEVECATQLRRFGDKLNFRQKLLNLISKLFCSGT
DEEEQILAKIVELLKYSGDQLERK
KRGAKPVTNFVKNLSALSDWYSVYTSAIAFT
SEEEVVEGEKEVEALKKSADWVSDWSSRPENIPPK
GEPCSFDVAIIAGRLRMLGDQFNGELEASAKNVIAETIKGQ
DSESQEDIIRNIARHLAQVGDSMDRSIPPGLVNGLALQLRNTSRSEE
ADKSDPKPGVMTQEVGQLLQDMGDDVYQQYRSLTRQSSDFDTQSGFSIN
ASMRQAEPADMRPEIWIAQELRRIGDEFNAYYARR
GFIQDRAGRMGGEAPELALDPVPQDASTKKLSECLKRIGDELDSNMELQR
MCPCPLHRGRGPPAVCACSAGRLGLRSSAAQLTAARLKALGDELHQRTMWRRRARSRRAPAPGALPTYWPWLCAAAQVAALAAWLLGRRNL

BIK
RAD9A
BAK1
PMAIP1/NOXA
BCL2L14/BCL-G
GRAMD4
BNIP3L/NIX
BCL2L15/BFK
BID
HUWE1/MULE
BCL2L11/BIM
BAX
HRK

GNAGYRLPLPASFPAVLPIGEQPPEGQWQHQAEVQIARKLQCIADQFHRLHVQQ

BMF

GPQPSLSLAEQHLESPVPSAPGALAGGPTQAAPGVRGEEEQWAREIGAQLRRMADDLNAQYERR

BBC3/PUMA

GAGAVEIRSRHSSYPAGTEDDEGMGEEPSPFRGRSRSAPPNLWAAQRYGRELRRMSDEFVDSFK
With the exception of BECN1 (see Table 2), the BH3 motif in BH3-only BCL2 family proteins is encoded by a single short exon [29].
Known and putative BH3 motifs are in underlined bold blue type.
Red highlighting indicates an amino acid encoded across a splice junction.
Amino acid sequences are from the CCDS dataset (http://www.ncbi.nlm.nih.gov/projects/CCDS/CcdsBrowse.cgi).

BAD
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Table 2. BH3 Motifs Encoded by Two Exons
RMMSTESANSFTLIGEASDGGTMENLSRRLKVTGDLFDIMSGQTDVDHPLCEECTDTLLDQLDTQLNVTENECQNYK

BECN1

GAATQQEFYAKNSRWTEGLISASKAVGWGATQLVEAADKVVLHTGKYEELIVCSHEIAASTAQLVAASK

HIP1R

VWQGLDVVRTSRALIGATNPADAPPGTIRGDFCIEVGKNLIHGSDSVESARREIALWFRADELLCWEDSAGHWLYE

NME3

VEDDSDAETYGEENDEQGNYSKRKIVSNWDRYQDIEKEVNNESGESQRGTDFSVLLSSAGDSFSQFRFAEEKEWDSEASCPKQ

AVEN

EMPDSAAALLGTCCKLQIIPTLCHLLRALSDDGVSDLEDPTLTPLKDTERFGIVQRLFASADISLERLKSSVKAVILKDSKVFPLLLCITLNGLCALGREHS

DFNA5

MEVLRRSSVFAAEIMDAFDRSPTDKELVAQAKALGREYVHARLLRAGLSWSAPERAAPVPGRLAEVCAVLLRLGDELEMIRPSVYRNVARQLHISLQSEPVVTDAFLAVAGHIFSAG
BOK
Prior to the discovery of BECN1, BOK (a multidomain pro-apoptotic protein) was the only BCL2 family member in which the BH3 motif was found to be encoded by two exons
[29].
Known and putative BH3 motifs are in underlined bold type.
Blue highlighting indicates a different exon.
Red highlighting indicates an amino acid encoded across a splice junction.
Amino acid sequences are from the CCDS dataset (http://www.ncbi.nlm.nih.gov/projects/CCDS/CcdsBrowse.cgi).

bind to inositol lipid determinants of clathrin-coated vesicles,
early endosomes, and recycling endosomes via their ANTH
domains, causing the endocytic machinery to favor continued signaling either by stabilizing the early endosome or
by stimulating growth factor receptor recycling to the cell
surface.
Conflicting data exists as to whether overexpression of
HIP1 has pro-apoptotic [57,58] or anti-apoptotic functions
[59]. In particular, Rao and colleagues found that expression
of an ANTH deletion mutant of HIP1, but not full-length
HIP1, induced cell death in a dominant interfering manner
[59]. The authors noted that two other reports of proapoptotic activity used a different HIP1 cDNA which lacked
the N-terminal sequence encoded by an upstream exon that
had not been previously appreciated [60]. Thus, they suggested that the reason for the discrepancy may be that cDNA
used in the previous studies was functionally similar to the
ANTH deletion mutant of HIP1 that they used. Following up
on the HIP1 findings, Hyun and coworkers reported that a
HIP1R mutant lacking the ANTH domain but not full-length
HIP1R similarly induced apoptosis after ectopic expression
in HEK293T cells [52].
Recently, HIP1R was identified in a screen for interacting partners of BCL2L10 (human DIVA or BCL-B), a
member of the BCL2 family that can either function as a
pro- or anti-apoptotic protein [61]. Under the conditions
employed in that study, ectopic expression of HIP1R
induced apoptosis and augmented BCL2L10 association with
caspase 9. In addition, a member of the proapoptotic BCL2
family, BAK, was required for HIP1R to induce cell death,
while BAX was dispensable. Deletion of both the N-terminal
ANTH domain and the C-terminal talin-like domain of
HIP1R greatly compromised its binding ability to BCL2L10.
The C-terminal deletion (amino acids 816-1068) encompassed a putative BH3 motif (amino acids 882-894) that we
identified (GATQLVEAADKVV; Table 2).
In addition to its well-accepted role as an antagonist of
apoptosis, BCL2 has also been reported to function as a
regulator of cell motility by interacting with and enhancing
actin polymerization [62,63]. Besides binding to actin [47], it
is evocative that HIP1R was identified in a proteomic screen
for proteins that interact with dynein light chain LC8
(although incorrectly listed as HIP1 in Table 2 of Ref. [64]).
LC8 is a component of the dynein motor complexes that

selectively sequester the the BIML and BIMEL isoforms of
BIM and so regulate their cell death-inducing functions [6567]. In response to cellular damage that affects the cell
cytoskeleton, BIM-LC8 complexes are released into the
cytoplasm where they can interact with anti-apoptotic BCL2
proteins, via their BH3 domains. These latter observations
suggest further parallels between HIP1R and typical BH3only proteins.
Putative BH3-Containing
Apoptosis

Proteins

Associated

with

NME3
NME3 (non-metastatic cells 3) is a member of a family
of 10 genes in humans named after the prototypic member
NME1, which was identified as a suppressor of tumor
metastasis (Nm23-H1) and exhibits nucleoside diphosphate
kinase activity [68,69]. NME proteins are involved in a
variety of physiological and pathological cellular processes
including cell proliferation, differentiation, vesicular trafficking and adhesion as well as apoptosis [70]. Phylogenetic
analysis of NME proteins shows two strongly supported
distinct clusters, with NME3 belonging to same group as
NME1, NME2 and NME4 [71].
NME3 was first identified as a gene associated with the
blast crisis phase of chronic myeloid leukemia [72]. A characteristic feature of blast crisis is the differentiation arrest of
the malignant hematopoietic progenitor cells. Constitutive
expression of NME3 in a myeloid precursor cell line, which
is growth-factor dependent for both proliferation and differentiation, resulted in inhibition of differentiation. Notably,
in the cell line model, differentiation arrest was associated
with apoptotic cell death [72]. The mechanisms responsible
for differentiation arrest and induction of apoptosis in this
system are not known. A role for NME3 in the regulation of
differentiation and apoptosis was also reported in neuroblastoma cells. However, in this situation overexpression of
NME3 promoted differentiation while protecting the cells
from apoptosis induced by serum deprivation [73]. The
effects of NME3 expression thus seem to be dependent on
cellular context.
We identified a putative BH3 motif in NME3 encompassing amino acids 129-141 (VGKNLIHGSDSVE; Table
2). That NME3 might associate with BCL2 family members
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is suggested from studies with the related human and rat
NME2 proteins. NME2 was identified in a screen for
proteins that interact with BCL2L10, a member of the BCL2
family that can either function as a pro- or anti-apoptotic
protein, described above [74]. BCL2L10 resides in the membranes of intracellular organelles [75] and can translocate
from endoplasmic reticulum to mitochondria upon apoptotic
stimulus [76]. Kang and colleagues showed that ectopic
expression of NME2 in HEK293T cells induced apoptosis
where it colocalized with BCL2L10 in the cytoplasm. NME3
has been reported to be localized within the cytoplasm and,
at least partly, within mitochondria although no specific
mitochondrial targeting sequence has been found [73,77].
NME2 contains a variant of the putative BH3 motif found in
NME3 (VGRNIIHGSDSVE) encompassing amino acids
112-124) which would satisfy a broader consensus definition
but was not identified in our screen because of a conservative substitution of the Φ2 hydrophobic L with isoleucine.
DFNA5
The DFNA5 (deafness, autosomal dominant 5) gene was
first identified as a gene whose expression is inversely correlated with that of the estrogen receptor in breast carcinomas
(accordingly, it was initially designated as ICERE-1 for
inversely correlated with estrogen receptor expression) [78]
and independently as a gene causing autosomal dominant
hearing loss [79]. Epigenetic silencing of DFNA5 in several
types of cancer, including a large percentage of gastric,
colorectal and breast cancers, have implicated DFNA5 as a
tumor suppressor gene [80-82].
In one study, decreased expression of DFNA5 in melanoma cell lines correlated with increased resistance to etoposide-induced apoptosis [83]. Subsequent work identified
DFNA5 as a p53 target gene and its ectopic expression
enhanced etoposide-induced cell death [84]. Intriguingly, in
the same study, ectopic expression of DFNA5 in TP53-negative lung cancer cells inhibited etoposide-induced cell death.
These contrasting results suggested that DFNA5 plays a role
in the p53-regulated cellular response to genotoxic stress by
somehow cooperating with p53, although the function of
DFNA5 in this process remains to be elucidated. The
DFNA5 gene has also be reported to be a glucocorticoidinducible gene in T cell acute lymphoblastic leukemia cells.
Induction of DFNA5 mRNA correlates with glucocorticoiddependent apoptosis of the cells. In this case, however, its
expression alone was not sufficient for apoptosis induction
[85].
A potential explanation for the differing results and
insight into the mechanism of DFNA5-induced hearing loss
was provided by identification of a fifth family with the disorder [86]. Comparative analyses of the five mutant DFNA5
genes revealed different mutations but in each case the
DFNA5 mRNA transcript was found to skip exon 8, resulting in a frameshift and a premature truncation of the protein.
These findings suggested that DFNA5-associated hearing
loss is attributable to a highly specific gain-of-function mutation, in which skipping of one exon causes disease. Experimental evidence congruent with this hypothesis was previously provided by the finding that transfection of mutant
DFNA5 causes cell death [87]. Following up on these
observations, de Beeck and coworkers recently demonstrated
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that DFNA5 is composed of two domains, separated by a
hinge region. The first region (exon 2-exon 7) induces apoptosis when transfected in HEK293T cells, leading to the
speculation that the second region may mask this domain
and regulate its apoptosis inducing capability [88]. The
DFNA5 exon 2-exon 7 construct was expressed mainly at
the plasma membrane. In addition, it was observed in the
cytoplasm in a granulated manner. The putative BH3 motif
in DFNA5 is formed across the splice junction of exons 9
and 10 (LCHLLRALSDDGV; Table 2). Therefore, a potential scenario is that the BH3-like domain encoded by exons 9
and 10 of DFNA5 facilitates association of the protein with
BCL2 family members. Mutations causing hearing loss or
experimental truncation of the protein disrupt these interactions, releasing the amino terminal portion of the protein to
initiate apoptosis by as yet unknown mechanisms. The varying effects of wild-type DFNA5 observed in the different
cancer apoptosis studies may relate to levels of the protein
expressed, and indicate a requirement for p53.
CONCLUSIONS
We have identified a number of potential BH3-only
proteins which can now be evaluated by direct experimentation for BH3 domain-mediated interactions with BCL2
family members and regulation of cell death mechanisms. In
addition to the candidates highlighted in the text, the list
provided as Supplemental File 2 should prove to be a useful
resource for further data mining of novel BH3-containing
proteins. It is important to note, however, that this list is by
no means a comprehensive compilation of all potential BH3only proteins in the human proteome. For example, the proapoptotic proteins BNIP1 and BNIP3 [89], which contain
diverged BH3 motifs (Supplemental File 1), were not identified by this screen; nor were several other purported novel
BH3-only proteins with atypical BH3-like sequences: such
as MOAP1/MAP-1 (modulator of apoptosis) [90], SPIKE
(small protein with inherent killing effect) [91], BLID/
BRCC2 (BH3-like motif containing, cell death inducer) [92],
TGM2 (tissue transglutaminase) [93], APOL6 (apolipoprotein L6) [94], APOL1 (apolipoprotein L1) [95] or HEBP2/
SOUL [96]. Clearly, further relaxation in the stringency of
the BH3 motif definition, and refinement of PSSM models
and molecular dynamics simulations will be necessary to
extend this strategy in order for it to become all inclusive.
We were struck by the fact that besides apoptosis the list
of potential BH3-only candidates identified by the 13-amino
acid BH3 consensus sequence that we employed is enriched
for proteins associated with autophagy (beyond BECN1) as
well as a broad spectrum of cellular stress responses such as
endoplasmic reticulum stress, oxidative stress, antiviral
defense and the DNA damage response (Supplemental File
2). It seems possible that some of the BH3-like sequences, if
not bona fide BH3 domains belonging to novel BCL2 family
members, represent core modules that participate in proteinprotein interactions transmitting various stress signals to
mitochondria and the nucleus, facilitating crosstalk between
apoptotic pathways and those involved in autophagy and cell
cycle checkpoint control [97-99]. In accord with this
conjecture, during the writing of this manuscript Kimchi and
colleagues published the results of a study in which they
identified the autophagy protein ATG12 as a novel BH3-
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Fig. (4). Known and hypothetical interactions between selected autophagy, DNA damage checkpoint, and apoptotic proteins. Known
physical associations for ATG12, ATG16L1, AVEN and BECN1 were imported from BioGrid (http://thebiogrid.org/). Binding of ATG12 to
BCL2 via a BH3-like motif was reported in Ref. [100]. A putative interaction between ATG16L1 and a representative anti-apoptotic BCL2
family member (BCL2) is indicated. Proteins highlighted in red were recovered in the screen for new BH3-containing protein candidates.

only proapoptotic protein that binds to BCL2 and MCL-1
[100]. ATG12 is not present in our list of candidates because
its atypical BH3-like region deviates from our consensus
motif at two positions. However, one of the other autophagy
genes that they identified as a positive regulator of apoptosis
but did not characterize, ATG16L1, is present (Supplemental
File 2, page 48) (Fig. 4).
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